What Is Sarcomatoid Mesothelioma Prognosis Treatment?

Sarcomatoid mesothelioma is the rarest and most aggressive form of mesothelioma, a cancer caused by asbestos exposure. It accounts for roughly 10 to 20 percent of all mesothelioma cases. The prognosis is poor because this type spreads quickly and does not respond well to standard treatments. Treatment focuses on slowing the disease, managing symptoms, and improving quality of life rather than achieving a cure.

What Is Sarcomatoid Mesothelioma?

Sarcomatoid mesothelioma is a subtype of malignant mesothelioma. Mesothelioma develops in the mesothelium, the thin tissue that lines the lungs, chest wall, abdomen, and heart. Unlike the more common epithelioid type, sarcomatoid cells look like spindle-shaped cells under a microscope. They resemble cells found in other soft tissue cancers, which makes this form harder to diagnose accurately.

The sarcomatoid subtype is the most aggressive of the three main mesothelioma cell types. The other two are epithelioid and biphasic, which contains both epithelioid and sarcomatoid cells. Because sarcomatoid cells divide quickly and spread easily, the cancer is often advanced by the time it is found.

What Causes Sarcomatoid Mesothelioma?

Asbestos exposure is the primary cause of sarcomatoid mesothelioma. Asbestos is a group of naturally occurring minerals made of microscopic fibers. When these fibers are inhaled or swallowed, they can become lodged in the mesothelium. Over decades, the fibers cause chronic inflammation and scarring. This damage can eventually lead to the DNA changes that cause cancer.

The time between asbestos exposure and a mesothelioma diagnosis is long. Most people are diagnosed 20 to 50 years after their first exposure. People who worked in construction, shipyards, insulation, automotive repair, and manufacturing faced the highest risk. Family members of these workers also faced risk from fibers carried home on clothing and hair.

Not everyone exposed to asbestos develops mesothelioma. The risk depends on the duration and intensity of exposure, the type of asbestos, and individual genetic factors. Smoking does not cause mesothelioma, but it increases the risk of lung cancer in people who have also been exposed to asbestos.

What Is the Prognosis for Sarcomatoid Mesothelioma?

The prognosis for sarcomatoid mesothelioma is the poorest of all mesothelioma subtypes. Most people survive 6 to 12 months after diagnosis. This is significantly shorter than the median survival for epithelioid mesothelioma, which is often 18 months or longer with treatment.

Several factors explain the poor outlook. Sarcomatoid cells grow and spread faster than other mesothelioma cell types. They are also more resistant to chemotherapy and radiation. By the time symptoms appear, the cancer has usually spread beyond the mesothelium to nearby tissues and organs.

Stage at diagnosis matters. People diagnosed at stage 1 or 2, when the cancer is still localized, have better outcomes than those diagnosed at stage 3 or 4. However, most sarcomatoid mesothelioma cases are found at advanced stages because early disease produces few or no symptoms.

Age and overall health also influence prognosis. Younger patients with no other serious health conditions tend to tolerate treatment better and live longer. Performance status, a measure of how well a person can carry out daily activities, is one of the strongest predictors of survival in mesothelioma patients.

How Is Sarcomatoid Mesothelioma Diagnosed?

Diagnosing sarcomatoid mesothelioma is challenging. Its cells look similar to other spindle cell cancers, such as sarcomatoid carcinoma of the lung and primary pleural sarcoma. Misdiagnosis is not uncommon.

The diagnostic process usually begins with imaging. A chest X-ray may show pleural thickening or fluid around the lungs. A CT scan provides more detail and can show tumor size and spread. An MRI or PET scan may be used to check whether the cancer has moved into nearby structures.

Imaging alone cannot confirm the diagnosis. A biopsy is required. In a biopsy, a surgeon or radiologist takes a small sample of the tumor tissue. A pathologist examines the cells under a microscope and runs special tests called immunohistochemistry. These tests look for specific proteins on the cell surface that help distinguish mesothelioma from other cancers.

Sarcomatoid mesothelioma cells often show low levels of the proteins typically found in epithelioid mesothelioma, such as calretinin and WT-1. This makes the diagnosis harder to confirm. In some cases, a second opinion from a pathologist who specializes in mesothelioma is necessary.

What Treatments Are Available for Sarcomatoid Mesothelioma?

Treatment for sarcomatoid mesothelioma depends on the stage of the disease, the patient’s overall health, and how far the cancer has spread. Because this subtype is aggressive and resistant to many therapies, treatment is usually aimed at controlling symptoms and extending life rather than curing the disease.

Surgery is an option for only a small number of patients. For the cancer to be removable, it must be confined to one side of the chest with no spread to distant organs. The two main surgeries are pleurectomy with decortication, which removes the pleura and visible tumor, and extrapleural pneumonectomy, which removes the lung, pleura, diaphragm, and part of the pericardium. Both are major operations with significant risks. Sarcomatoid patients are often not offered surgery because the cancer tends to return quickly even after complete removal.

Chemotherapy is the standard first-line treatment for mesothelioma. The usual combination is cisplatin or carboplatin with pemetrexed. This regimen extends survival in epithelioid mesothelioma, but its benefit in sarcomatoid disease is smaller. Some studies suggest that sarcomatoid tumors respond less to chemotherapy because of their biology, but the regimen is still offered because it is the only treatment proven to improve survival in clinical trials.

Radiation therapy is used to relieve pain and other symptoms caused by tumor growth. It is not typically used as a curative treatment for sarcomatoid mesothelioma. Radiation may be given after surgery to reduce the chance of local recurrence, but evidence for this benefit in sarcomatoid disease is limited.

Immunotherapy has changed the treatment landscape for mesothelioma. The combination of ipilimumab and nivolumab was approved for mesothelioma based on a clinical trial that showed improved overall survival compared to chemotherapy. This benefit was seen across all cell types, including sarcomatoid. For some patients, immunotherapy offers a better response than chemotherapy.

Clinical trials are another option. Researchers are studying targeted therapies, new drug combinations, and novel treatment approaches specifically for sarcomatoid mesothelioma. Patients should ask their oncologist whether any trials are available at their treatment center.

What Are the Symptoms of Sarcomatoid Mesothelioma?

Sarcomatoid mesothelioma most often develops in the pleura, the lining around the lungs. Common symptoms include shortness of breath, chest pain, a persistent cough, and unexplained weight loss. Fluid buildup around the lungs, called pleural effusion, is common and can make breathing difficult.

When the cancer starts in the peritoneum, the lining of the abdomen, symptoms include abdominal swelling, pain, nausea, and changes in bowel habits. Peritoneal mesothelioma is less common than pleural mesothelioma but can also be sarcomatoid.

These symptoms are not specific to mesothelioma. They overlap with many other lung and abdominal conditions. This is another reason why diagnosis is often delayed. Anyone with a history of asbestos exposure who develops these symptoms should tell their doctor about that exposure history.

What Is Palliative Care and Why Does It Matter?

Palliative care focuses on relieving symptoms and improving quality of life. For sarcomatoid mesothelioma patients, palliative care is a central part of treatment from the time of diagnosis. It is not the same as hospice care, though hospice is a form of palliative care used at the end of life.

Palliative treatments include draining pleural fluid, pain management, oxygen therapy, and medications for breathlessness. These measures do not treat the cancer itself, but they make daily life more manageable. Many patients benefit from a palliative care team working alongside their oncology team.

Research shows that early palliative care improves quality of life and may even extend survival in some cancer patients. It is a standard part of comprehensive cancer care and should not be seen as giving up.